Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31163069 | 0.90 | POLB (0.42) | PYCR1AAK1SOS1POLBMEN1 | |
| SCHEMBL20054017 | 0.90 | POLB (0.42) | PYCR1AAK1SOS1POLBMEN1 | |
| SCHEMBL8168487 | 0.86 | FPR3 (0.39) | PYCR1AAK1SOS1MEN1KMT2A | |
| SCHEMBL18719607 | 0.86 | POLB (0.43) | AAK1SOS1POLBMEN1KMT2A | |
| SCHEMBL12068165 | 0.85 | RIPK1 (0.47) | PYCR1AAK1SOS1POLBHTR2C | |
| SCHEMBL31137753 | 0.85 | RIPK1 (0.47) | PYCR1AAK1SOS1POLBHTR2C | |
| SCHEMBL2884008 | 0.84 | HPGD (0.43) | AAK1SOS1POLBMEN1KMT2A | |
| SCHEMBL29211248 | 0.83 | ALDH1A1 (0.43) | AAK1SOS1POLBMEN1KMT2A | |
| SCHEMBL12231498 | 0.82 | HTR2C (0.39) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL20461244 | 0.81 | POLB (0.40) | AAK1SOS1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032019-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | PYCR1 4152/4885AAK1 706/4885SOS1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.